Back

Comparative 1-year outcomes of dofetilide vs amiodarone for atrial fibrillation in hypertrophic cardiomyopathy: a propensity-matched study

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation miscellaneous Rhythm Control, Antiarrhythmic Drugs EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Ayoyimika Okunlola

United Lincolnshire Hospitals and NHS trust, Boston (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Postoperative atrial fibrillation: function over fibrosis, prevention needed
Professor H. Wang (Shenyang, CN)
Abstract Slides Video
Presentation thumbnail
Recent trends and future projections in atrial fibrillation epidemiology: a european population-based study
Doctor J. Rodriguez Garcia (Hospitalet De Llobregat, ES)
Abstract Slides Video
Presentation thumbnail
Impairment of left atrial function following pulsed-field ablation for persistent atrial fibrillation.
Doctor M. Hozman (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA
Doctor M. Frausing (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Heart failure over time in patients with screening detected atrial fibrillation - a postdoc analysis of the STROKESTOP and STROKESTOP II studies
Doctor G. Sado (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation miscellaneous
Video

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Session
Atrial fibrillation miscellaneous
thumbnail
Congress Session
Late-Breaking Clinical Science: spectrum of cardiomyopathies
thumbnail
Congress Session
Treatment of atrial fibrillation: there is more than ablation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources